|
應(yīng)國(guó)光,，博士,，教授,，PI,，博士生導(dǎo)師。天津市腫瘤研究所副所長(zhǎng),，腫瘤細(xì)胞生物學(xué)實(shí)驗(yàn)室主任,。天津市腫瘤防治重點(diǎn)實(shí)驗(yàn)室主任，天津市醫(yī)學(xué)健康領(lǐng)域重點(diǎn)實(shí)驗(yàn)室創(chuàng)新戰(zhàn)略聯(lián)盟理事長(zhǎng),。畢業(yè)于清華大學(xué)化學(xué)系、都靈大學(xué)醫(yī)學(xué)院和米蘭Mario Negri藥理研究所,。1986-1992年上海生物制品研究所國(guó)家科委基因工程中心助研,。2007年任職于天津醫(yī)科大學(xué)附屬腫瘤醫(yī)院,。歷年主要學(xué)術(shù)貢獻(xiàn)包括：參與完成國(guó)家863計(jì)劃人基因工程產(chǎn)品的中試研究及產(chǎn)業(yè)化開發(fā)，獲國(guó)家科技進(jìn)步一,、二等獎(jiǎng),。克隆鑒定T160/SSRP1與cross-form DNA的相互作用,，提出結(jié)構(gòu)識(shí)別為特征的基因擴(kuò)增及轉(zhuǎn)錄調(diào)控假說(shuō),。發(fā)現(xiàn)Nucleolin為Myb原癌基因轉(zhuǎn)錄協(xié)同子以及不同Myb分子的組織特異轉(zhuǎn)錄活性機(jī)制。發(fā)現(xiàn)FPRL1/FPR2為神經(jīng)細(xì)胞保護(hù)因子Humanin的天然受體,，闡明Humanin抗Aβ的神經(jīng)保護(hù)機(jī)制,。最先展開具有特異膜調(diào)控潛能的EHD新基因家族的系統(tǒng)比較與功能研究，并圍繞膜轉(zhuǎn)運(yùn)機(jī)制對(duì)關(guān)鍵受體胞內(nèi)轉(zhuǎn)運(yùn)與細(xì)胞信號(hào)傳導(dǎo),、其異變?cè)谀[瘤中的生物學(xué)作用及其臨床轉(zhuǎn)化應(yīng)用前景,、路線和策略等方面進(jìn)行探索。學(xué)術(shù)論文四十余篇發(fā)表于The Journal of Biological Chemistry,、the Journal of Immunology等國(guó)際專業(yè)期刊,。
主要獎(jiǎng)勵(lì)
1992歐共體瑪麗亞·居里獎(jiǎng)學(xué)金
1993中國(guó)國(guó)家科技進(jìn)步一等獎(jiǎng)，人基因工程a1干擾素的研制,，主要研制者之一
1994意大利腫瘤合作協(xié)會(huì)獎(jiǎng)學(xué)金
1995中國(guó)國(guó)家科技進(jìn)步二等獎(jiǎng),，人基因工程γ干擾素的研制、中試生產(chǎn)及臨床應(yīng)用,，主要研制者之一
1995衛(wèi)生部科技進(jìn)步一等獎(jiǎng),，基因工程γ干擾素的研制、中試生產(chǎn)及臨床應(yīng)用,，主要研制者之一
研究基金
2008.1-2010.12 EHD蛋白對(duì)ErbB受體的轉(zhuǎn)運(yùn)調(diào)控機(jī)制研究,國(guó)家自然科學(xué)基金,，主持項(xiàng)目。
2009.10-2012.9非激素依賴性前列腺癌的蛋白組學(xué)和分子靶向研究,天津市科委CMM-天津合作基金,，合作項(xiàng)目,。
2010.1-2014.8 iCSCs侵襲和轉(zhuǎn)移相關(guān)預(yù)警分子篩查及意義研究(腫瘤干細(xì)胞在惡性腫瘤發(fā)生發(fā)展中的作用及機(jī)理研究)，國(guó)家973計(jì)劃項(xiàng)目子課題,，合作項(xiàng)目,。
2011.1-2013.12膜轉(zhuǎn)運(yùn)調(diào)節(jié)蛋白EHD的核功能及其影響乳腺病變的機(jī)制研究，國(guó)家自然科學(xué)基金,主持項(xiàng)目,。
2012.1-2014.12天津?yàn)I海新區(qū)聯(lián)合攻關(guān)合作項(xiàng)目,。
特約審評(píng)
2001- The Journal of Biological Chemistry; International Journal of Pharmacology; International Journal of Radiation, Oncology and BioPhysics
學(xué)術(shù)兼職
2009-中華醫(yī)學(xué)會(huì)醫(yī)學(xué)細(xì)胞生物學(xué)分會(huì)委員
2011-中國(guó)抗癌協(xié)會(huì)腫瘤病因?qū)W分會(huì)委員
2011-中國(guó)抗癌協(xié)會(huì)腫瘤轉(zhuǎn)移分會(huì)委員
2011- 《中國(guó)腫瘤臨床》副主編
2011- 《Clinical Oncology and Cancer Research》編委
近三年主要論文
1. Chen,Y.Z., Chen,Z., Gong,Y.A., and Ying,G. 2012. SUMOhydro: A Novel Method for the Prediction of Sumoylation Sites Based on Hydrophobic Properties. PLoS One 7:e39195.
2. Duo,J., Ying,G.G., Wang,G.W., and Zhang,L. 2012. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Mol Med Report. 5:1453-1456.
3. Li,H., Wu,J., Ying,G., Chen,L., Lai,L., Liu,Z., Zhang,N., and Guo,H. 2012. J-4: a novel and typical preclinical anticancer drug targeting protein kinase C zeta. Anticancer Drugs 23:691-697.
4. Ding,T., Ma,Y., Li,W., Liu,X., Ying,G., Fu,L., and Gu,F. 2011. Role of aquaporin-4 in the regulation of migration and invasion of human glioma cells. Int J Oncol 38:1521-1531.
5. Duan,L., Raja,S.M., Chen,G., Virmani,S., Williams,S.H., Clubb,R.J., Mukhopadhyay,C., Rainey,M.A., Ying,G., Dimri,M. et al 2011. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J Biol Chem 286:620-633.
6. George,M., Rainey,M.A., Naramura,M., Foster,K.W., Holzapfel,M.S., Willoughby,L.L., Ying,G., Goswami,R.M., Gurumurthy,C.B., Band,V. et al 2011. Renal Thrombotic Microangiopathy in Mice with Combined Deletion of Endocytic Recycling Regulators EHD3 and EHD4. PLoS One 6:e17838.
7. Ma,Y., Wang,B., Li,W., Liu,X., Wang,J., Ding,T., Zhang,J., Ying,G., Fu,L., and Gu,F. 2011. Intersectin1-s is involved in migration and invasion of human glioma cells. J Neurosci. Res 89:1079-1090.
8. Wang,B., Yang,D., Sun,B., Wei,X., Guo,H., Liu,X., Ying,G., Niu,R., Zhang,N., and Ma,Y. 2011. An anti-tumor nanoparticle, [Gd@C82(OH)22]n, induces macrophage activation. J Nanosci Nanotechnol 11:2321-2329.
9. Chen,K., Le,Y., Liu,Y., Gong,W., Ying,G., Huang,J., Yoshimura,T., Tessarollo,L., and Wang,J.M. 2010. A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses. J Immunol 184:3331-3335.
10. Duan,L., Chen,G., Virmani,S., Ying,G., Raja,S.M., Chung,B.M., Rainey,M.A., Dimri,M., Ortega-Cava,C.F., Zhao,X. et al 2010. Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture. J Biol Chem 285:1555-1568.
11. George,M., Rainey,M.A., Naramura,M., Ying,G., Harms,D.W., Vitaterna,M.H., Doglio,L., Crawford,S.E., Hess,R.A., Band,V. et al 2010. Ehd4 is required to attain normal prepubertal testis size but dispensable for fertility in male mice. Genesis 48:328-342.
12. Ma,Y., Wang,B., Li,W., Ying,G., Fu,L., Niu,R., and Gu,F. 2010. Reduction of intersectin1-s induced apoptosis of human glioblastoma cells. Brain Res 1351:222-228.
13. Rainey,M.A., George,M., Ying,G., Akakura,R., Burgess,D.J., Siefker,E., Bargar,T., Doglio,L., Crawford,S.E., Todd,G.L. et al 2010. The endocytic recycling regulator EHD1 is essential for spermatogenesis and male fertility in mice. BMC Dev Biol 10:37.
14. Wu,J., Zhang,B., Wu,M., Li,H., Niu,R., Ying,G., and Zhang,N. 2010. Screening of a PKC zeta-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis. Invest New Drugs 28:268-275.
15. Guo,H., Ma,Y., Zhang,B., Sun,B., Niu,R., Ying,G., and Zhang,N. 2009. Pivotal Advance: PKCzeta is required for migration of macrophages. J Leukoc Biol 85:911-918.
16. Liu,Y., Wang,J., Wu,M., Wan,W., Sun,R., Yang,D., Sun,X., Ma,D., Ying,G., and Zhang,N. 2009. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 7:944-954.
17. Zhang,B., Ma,Y., Guo,H., Sun,B., Niu,R., Ying,G., and Zhang,N. 2009. Akt2 is required for macrophage chemotaxis. Eur J Immunol 39:894-901.
18. Zhang,F., Zhang,L., Zhang,B., Wei,X., Yang,Y., Qi,R.Z., Ying,G., Zhang,N., and Niu,R. 2009. Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 8:5041-5047.
（腫瘤細(xì)胞生物學(xué)實(shí)驗(yàn)室）
|
